Related to MorphoSys Nabs Xencor’s Phase I B-Cell Malignancy Antibody for $13M Up Front

• Gene Variations Affect Risk of Hodgkin’s Disease
  
• Malfunction in Immune Response Pathway Is Key to How a Fused Gene Promotes Childhood Leukemia
  
• Karolinska and Biovitrum Create Joint Venture to Develop Latter's Preclinical Leukemia Treatment
  
• BMS Shells Out $400M to Extend Revenue-Sharing Period with Otsuka for Abilify
  
• ChemGenex Secures $7.1M to Advance Late-Stage Anticancer Agent
  
• Biovest’s Stock Value Triples with Phase III Data on Lymphoma Vaccine
  
• Scientists Pinpoint Enzyme Involved in Resistance to Childhood Leukemia Drug
  
• Spectrum Garners $9.5M in New Financing Round
  
• Spectrum Garners $10M in New Financing Round
  
• FDA Asks Spectrum Pharmaceuticals for Past Clinical Study Data to Help Expand Approval of NHL Drug
  
• Gloucester Pharmaceuticals Pockets $29M to Support T-Cell Lymphoma Drug Development
  
• European Commission Clears Wyeth Drug for Relapsed and Refractory Mantle Cell Lymphoma
  
• Scientists Uncover Molecular Pathway that Makes Tumors More Aggressive
  
• Phase III Shows Rituxan Maintenance Therapy Prolongs PFS in Follicular Lymphoma Patients
  
• Allos Wins Accelerated Approval of Folotyn in Relapsed or Refractory Peripheral T-cell Lymphoma
  
• Seattle Genetics Shutters B-Cell Lymphoma Program
  
• Genzyme's Label-Expansion Efforts for ALL Therapy Receive Setback from the FDA
  
• Kinaxo to Help Bayer Predict Patient Response to Nexavar in AML Clinical Trial
  
• Novartis’ New CML Drug Outperforms Gleevec as First-Line Therapy for Ph+ Disease